1. Home
  2. HRMY vs FORTY Comparison

HRMY vs FORTY Comparison

Compare HRMY & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$41.14

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Formula Systems (1985) Ltd.

FORTY

Formula Systems (1985) Ltd.

N/A

Current Price

$114.99

Market Cap

2.0B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
HRMY
FORTY
Founded
2017
1985
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.0B
IPO Year
2020
1998

Fundamental Metrics

Financial Performance
Metric
HRMY
FORTY
Price
$41.14
$114.99
Analyst Decision
Buy
Analyst Count
9
0
Target Price
★ $44.11
N/A
AVG Volume (30 Days)
★ 849.5K
433.0
Earning Date
05-07-2026
05-21-2026
Dividend Yield
N/A
★ 1.32%
EPS Growth
★ 7.97
N/A
EPS
★ 1.84
N/A
Revenue
★ $868,453,000.00
N/A
Revenue This Year
$19.75
N/A
Revenue Next Year
$12.88
N/A
P/E Ratio
★ $22.37
$36.65
Revenue Growth
★ 21.51
N/A
52 Week Low
$25.52
$102.01
52 Week High
$43.49
$190.56

Technical Indicators

Market Signals
Indicator
HRMY
FORTY
Relative Strength Index (RSI) 52.86 48.29
Support Level $40.92 $109.49
Resistance Level $43.38 $119.68
Average True Range (ATR) 1.21 1.67
MACD -0.27 0.09
Stochastic Oscillator 40.51 34.78

Price Performance

Historical Comparison
HRMY
FORTY

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.

Share on Social Networks: